Two experts see major challenges facing the adoption of new obesity drugs.
Dr. Kavita Patel, a physician and NBC News medical contributor, believes fresh data from Novo Nordisk on Ozempic's ability to delay the progression of chronic kidney disease is among the strongest supporting evidence for secondary uses of the drug.
However, she considers data supporting the use of…